KION GROUP AG (KIGRY) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
Group Order Intake: EUR10.3 billion, a 5% decline compared to the prior year.
Revenue: Record EUR11.5 billion for the full year 2024.
Adjusted EBIT: Increased 16% to EUR917 million; margin improved by 110 basis points to 8%.
Free Cash Flow: EUR702 million, slightly below last year but exceeded market expectations.
Earnings Per Share: EUR2.75, an increase of 18%.
ITS Segment Revenue: EUR2.3 billion, a 1% decline year over year.
ITS Segment Adjusted EBIT: EUR245 million with a margin of 10.6%.
SCS Segment Order Intake: EUR624 million, impacted by customer hesitancy.
SCS Segment Adjusted EBIT: EUR42 million with a margin of 5.4%.
Group Adjusted EBIT for Q4: EUR250 million with a margin of 8.2%.
Net Income for Q4: EUR111 million, earnings per share of EUR0.85.
Free Cash Flow for Q4: Positive EUR271 million.
Net Financial Debt: Decreased by EUR202 million to less than EUR1 billion.
2025 Revenue Guidance: EUR10.9 billion to EUR11.7 billion.
2025 Group Adjusted EBIT Guidance: EUR720 million to EUR870 million.
2025 Free Cash Flow Guidance: EUR400 million to EUR550 million.
Warning! GuruFocus has detected 6 Warning Signs with KIGRY.
Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
KION GROUP AG (KIGRY) achieved a record revenue of EUR11.5 billion in 2024, with an adjusted EBIT increase of 16% to EUR917 million.
Earnings per share rose by 18% to EUR2.75, and a dividend of EUR0.82 is proposed, maintaining a payout ratio of approximately 30%.
The company has made significant progress in operational and commercial agility, focusing on innovation, digitalization, and artificial intelligence.
KION GROUP AG (KIGRY) is enhancing its presence in the growing automation market through strategic partnerships with NVIDIA and Accenture.
The company reported a strong free cash flow of EUR702 million, exceeding capital market expectations despite being slightly below the previous year.
Group order intake declined by 5% to EUR10.3 billion, reflecting subdued markets in both operating segments during 2024.
The ITS segment experienced a 1% revenue decline year over year, with a 4% decline in the new truck business.
Order intake for the SCS segment was impacted by customer hesitancy due to macro and political uncertainty, with a 28% decline in Business Solutions orders.
The company anticipates a temporary decline in adjusted EBIT and margins for the ITS segment in 2025 due to less favorable product and geography mix and intensifying competition.
Free cash flow for 2025 is expected to be substantially below the prior year due to cash outflows from an efficiency program.
Q: Can you explain the assumptions behind the truck sales outlook for 2025, particularly regarding the order intake levels needed to achieve the high end of the guidance? A: Christian Harm, CFO: The revenue for 2025 is based on the order book we have so far. The normalization of the order book means revenue will follow the order intake throughout the year. We expect growth in ITS across different regions on a unit basis. On the upper end of the range, we anticipate an order intake similar to the prior year, while the lower end reflects a scenario where market revival does not occur as expected.
Q: Regarding the warehouse automation project pipeline, is customer hesitancy still a function of spare capacity, especially in e-commerce? A: Richard Smith, CEO: The e-commerce players have grown into the capacity built during COVID. We are returning to pre-COVID mid-term capacity planning with large e-commerce customers. This indicates that e-commerce players are coming back to the market, which is a positive sign for growth in the supply chain solutions market.
Q: Can you elaborate on the SCS revenue outlook, given the order intake in past years? A: Richard Smith, CEO: The SCS revenue outlook is supported by continued strong service growth and the ability to convert projects faster, particularly from large e-commerce players. This allows us to anticipate converting some orders within the year, supporting the upper end of the guidance.
Q: How should we view the quarterly trajectory of ITS margins in 2025? A: Christian Harm, CFO: The first quarter of 2025 is likely to have a relatively stronger margin for the ITS segment compared to subsequent quarters. The full impact of cost-efficiency measures will be realized in 2026, with Q1 potentially being stronger than the following quarters.
Q: What is the impact of intensifying competition, particularly from Chinese competitors, on your business? A: Richard Smith, CEO: We see increased competition, especially in Eastern Europe, from Chinese competitors entering the market at different pricing points. However, this is not a significant shift from previous quarters, as competition has always been strong in the market.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer
FDA Investigational Device Exemption (IDE) Approval enables Presidio's ULF platform technology to be tested in a pivotal clinical trial in the United States, representing a significant step in bringing this transformational technology to patients who suffer from chronic nociceptive low back pain. SAN MATEO, Calif., June 12, 2025--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the FULFILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is a patient-centric medical technology company developing a novel approach to treating chronic nociceptive low back pain with the goal of providing durable relief to an underserved patient population. The ULF neuromodulation platform is designed to target localized pain by reducing neuronal responses; suppression of these signals may reduce suffering for patients who have chronic nociceptive low back pain. There are currently no approved SCS treatment options for nociceptive back pain, which presents a $20B market opportunity. "IDE approval from the FDA represents a significant milestone for Presidio and enables the study of ultra low frequency modulation of the nervous system. The results from our first-in-human clinical trial in Australia, which were presented by Dr. Marc Russo at NANS earlier this year, were very encouraging. We are excited to now begin a more robust trial, which we believe will demonstrate the safety and efficacy of our ULF platform," said Michael Onuscheck, Presidio Medical's Chief Executive Officer. In addition, the company is pleased to announce Dimas Jiménez has joined as Chief Financial Officer (CFO). Mr. Jiménez brings over four decades of finance experience, spanning roles from Wall Street to both large and start-up life science organizations. He will be responsible for continuing to build the financial infrastructure of Presidio, supporting the commercialization efforts of our ULF neuromodulation system and expanding relationships with current and future investors. "We are extremely pleased to welcome Dimas to the Presidio team. The breadth and depth of his experience within the life science industry and his expertise in working with pre-commercialization start-up organizations is invaluable as we continue to grow and evolve as a company," said Onuscheck. "Presidio's ULF platform has the potential to greatly improve the lives of patients who suffer from debilitating chronic back pain. I've spent a significant amount of my career working with companies whose goal is to disrupt the status quo. I couldn't be more excited to be a part of this mission-driven and patient-centric organization," said Jiménez. Mr. Jiménez most recently served as the CFO of Spire Health and has held prior positions as CFO at StemoniX and Orphagen Pharmaceuticals. He has managed four company exits and has helped raise $670 million in capital for life science organizations. Mr. Jiménez received a Bachelor of Arts degree from Dartmouth College, a Master of Business Administration from Stanford University and is a Chartered Financial Analyst (CFA). About Presidio Medical Presidio Medical was founded in 2017 and is headquartered in San Mateo, CA. This clinical stage privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity, with a first indication in the treatment of chronic pain. Presidio's investors include Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital. For more information, visit: View source version on Contacts Media Contact Maureen ShayPresidio Medical, 650-502-1071 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Business Wire
Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer
SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the F ULF ILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is a patient-centric medical technology company developing a novel approach to treating chronic nociceptive low back pain with the goal of providing durable relief to an underserved patient population. The ULF neuromodulation platform is designed to target localized pain by reducing neuronal responses; suppression of these signals may reduce suffering for patients who have chronic nociceptive low back pain. There are currently no approved SCS treatment options for nociceptive back pain, which presents a $20B market opportunity. 'IDE approval from the FDA represents a significant milestone for Presidio and enables the study of ultra low frequency modulation of the nervous system. The results from our first-in-human clinical trial in Australia, which were presented by Dr. Marc Russo at NANS earlier this year, were very encouraging. We are excited to now begin a more robust trial, which we believe will demonstrate the safety and efficacy of our ULF platform,' said Michael Onuscheck, Presidio Medical's Chief Executive Officer. In addition, the company is pleased to announce Dimas Jiménez has joined as Chief Financial Officer (CFO). Mr. Jiménez brings over four decades of finance experience, spanning roles from Wall Street to both large and start-up life science organizations. He will be responsible for continuing to build the financial infrastructure of Presidio, supporting the commercialization efforts of our ULF neuromodulation system and expanding relationships with current and future investors. 'We are extremely pleased to welcome Dimas to the Presidio team. The breadth and depth of his experience within the life science industry and his expertise in working with pre-commercialization start-up organizations is invaluable as we continue to grow and evolve as a company,' said Onuscheck. 'Presidio's ULF platform has the potential to greatly improve the lives of patients who suffer from debilitating chronic back pain. I've spent a significant amount of my career working with companies whose goal is to disrupt the status quo. I couldn't be more excited to be a part of this mission-driven and patient-centric organization,' said Jiménez. Mr. Jiménez most recently served as the CFO of Spire Health and has held prior positions as CFO at StemoniX and Orphagen Pharmaceuticals. He has managed four company exits and has helped raise $670 million in capital for life science organizations. Mr. Jiménez received a Bachelor of Arts degree from Dartmouth College, a Master of Business Administration from Stanford University and is a Chartered Financial Analyst (CFA). About Presidio Medical Presidio Medical was founded in 2017 and is headquartered in San Mateo, CA. This clinical stage privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity, with a first indication in the treatment of chronic pain. Presidio's investors include Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital. For more information, visit:
Associated Press
4 days ago
- Associated Press
ITS World Congress Partners with SwRI to Lead the 2025 Future Leaders Program
Winners to present transportation solutions at the world's largest ITS conference 'We are investing in the next generation of transportation technology leaders by creating opportunities for students to showcase their innovative solutions on a global stage.'— Laura Chace, President and CEO of ITS America ATLANTA, GA, UNITED STATES, June 12, 2025 / / -- Southwest Research Institute (SwRI) is excited to sponsor the Future Leaders Program at ITS World Congress this year, organized in partnership by RX and ITS America (ITSA), taking place August 24-28 at the Georgia World Congress Center in Atlanta, Georgia. Through the Future Leaders Program, the next generation of ITS leaders will gather and have the opportunity to attend educational sessions, training sessions, meet with exhibitors, sponsors, and technology providers, and network with the global community of ITS professionals who can offer career advice and mentorship. College students are invited to share visions for the future of transportation in a global essay competition ahead of ITS World Congress 2025. Three winning students - one from Asia Pacific, Europe, and the Americas - will receive a paid trip to present their research at the event. 'We are investing in the next generation of transportation technology leaders by creating opportunities for students to showcase their innovative solutions on a global stage,' said Laura Chace, President and CEO of ITS America. 'The contributions from new talent will help shape how we build safer, greener, smarter transportation systems.' The competition requires students to address transportation challenges within their region that align with the conference theme 'Deploying Today, Empowering Tomorrow.' A panel of judges from ITS Asia-Pacific, ITS America, ERTICO, and Southwest Research Institute will select regional finalists before choosing three global winners. 'The Future Leaders Program connects students directly with industry pioneers,' said Josh Johnson, Executive Director of SwRI's Intelligent Transportation Systems Department. 'By presenting at ITS World Congress, students gain real-world experience sharing their research with transportation leaders from around the world.' The Future Leaders Program features a dedicated day of programming on Wednesday, August 27, including expert roundtable discussions, guided tours of exhibits and demonstrations, and resume reviews at the SwRI booth. Students from around the World and local Atlanta-area student groups will participate in special sessions designed to encourage careers in transportation technology. 'ITS World Congress creates life-changing opportunities for students to launch their careers in transportation technology,' said Jaime McAuley, Event Director for ITS America Events at RX Global. 'Winners receive conference admission, round-trip airfare, and access to exclusive networking events where they can connect with potential employers and mentors.' Students can register and view submission guidelines at The submission deadline is July 1, 2025. Danielle Baker 10 to 1 PR [email protected] Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
